Lymphedema in patients with X-linked severe combined immunodeficiency [0.03%]
伴发赖利道尔综合症的淋巴水肿患者治疗后的长期效果评估
Filippo Consonni,Suk See De Ravin,Stephane Vignes et al.
Filippo Consonni et al.
Background: IL2RG and JAK3 mutations cause T-cell-negative, B-cell-positive, natural killer cell-negative severe combined immunodeficiency (SCID). Cell therapies such as hematopoietic stem cell transplantation (or gene th...
Respiratory infections and asthma exacerbations in children: Regional insights into the overlooked role of atypical pathogens in Mexico [0.03%]
呼吸道感染和儿童哮喘加剧：对墨西哥地区典型病原体被忽视作用的见解
Victor Gonzalez-Uribe,Carlos Andres Gomez-Nuñez,Ricardo Martinez-Tenopala et al.
Victor Gonzalez-Uribe et al.
Background: Respiratory infections are the leading cause of asthma exacerbations in children, yet data from Latin America remain limited, especially in the postpandemic context. Understanding the respiratory pathogen land...
Birch rust allergy as a novel autumnal trigger of seasonal airway symptoms [0.03%]
白桦锈病过敏作为季节性呼吸道症状的新型秋季触发因素
Randi Falnes Olsen,Elin Ørbeck Vallevik,Thorsten Graf et al.
Randi Falnes Olsen et al.
Background: Accurate identification of allergenic triggers is essential for diagnosis, prevention, and management of airway allergies. In Tromsø (in northern Norway), birch rust (BR) spores are released in large quantiti...
Ashna Jain,Eliza Haffey,Kathryn Whiteside et al.
Ashna Jain et al.
Background: The estimated prevalence of food allergy (FA) among college students is 15%. However, the risk of FA, anaphylaxis, and related outcomes in college dining halls remains unclear. ...
Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study [0.03%]
CHRONICLE研究中重度哮喘和临床相关过敏患者的生物结局
Bradley E Chipps,Warner W Carr,Reynold A Panettieri Jr et al.
Bradley E Chipps et al.
Background: Several mAb biologic therapies are approved for the treatment of severe asthma. There are limited data examining biologic outcomes in patients with allergy that has been clinically confirmed to exacerbate thei...
Asthma biologic effectiveness by age and sex in the US CHRONICLE study [0.03%]
美国CHRONICLE研究中不同年龄和性别哮喘生物药疗效的差异性分析
Alan P Baptist,Weily Soong,Bradley E Chipps et al.
Alan P Baptist et al.
Background: Biologic therapies are effective in reducing asthma exacerbations in patients with severe asthma; however, the impact of age and sex on the real-world effectiveness of these therapies is not well understood. ...
Prediction model to identify patients with hypereosinophilic syndrome using real-world data [0.03%]
基于真实世界数据的高嗜酸性粒细胞综合征患者的预测模型
Paneez Khoury,Yen Chung,Donna Carstens et al.
Paneez Khoury et al.
Background: Hypereosinophilic syndrome (HES) is challenging to diagnose and identify in real-world data. Objective: We sought to develo...
Cephalosporin allergy: R1 side-chain and penicillin cross-reactivity patterns in an Australian cohort [0.03%]
头孢菌素过敏：澳大利亚队列中的R1侧链和青霉素交叉反应模式
Brittany Stevenson,Elizabeth Klinken,Michelle Trevenen et al.
Brittany Stevenson et al.
Background: Cross-reactivity between cephalosporins, and penicillins, is mainly explained by R1 side-chain similarity. However, data on cross-reactivity patterns in cephalosporin-allergic patients, with and without preexi...
First reported allergen immunotherapy anaphylaxis treated with neffy nasal spray: A case series [0.03%]
首例使用NEFFY鼻喷雾治疗的过敏免疫疗法过敏性休克病例系列报告
Jake Rosenblum,Gregory Puglisi,Joseph Grillo
Jake Rosenblum
The neffy intranasal epinephrine delivery system was recently approved by the US Food and Drug Administration; however, published information on its real-world use is limited. Immunotherapy patients reacting in our clinic experienced prompt...
Real-world treatment patterns in patients with chronic rhinosinusitis with nasal polyps who initiated dupilumab: A US claims analysis [0.03%]
美国理赔分析：Dupixent初治慢性鼻窦炎伴鼻息肉患者的真实世界治疗模式
Jayant M Pinto,Mirko Fillbrunn,Bruno Martins et al.
Jayant M Pinto et al.
Background: Dupilumab was approved as an add-on maintenance treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps based on the pivotal phase 3 trials. ...